To further investigate the impact of ERβ localization on EGFR-TKI efficacy, we analyzed correlations between ERβ localization (cytoplasmic and/or nuclear) and survival after EGFR-TKI therapy in 184 Chinese patients with advanced NSCLC and confirmed the clinical results in lung cancer cell lines. Here, ESR2 is linked to lung carcinoma.